Samsung Electronics, multinational electronics leader has entered a joint commercial partnership agreement with WellDoc to deliver a best-in-class digital health solution for individuals living with diabetes. The companies will integrate WellDoc’s newly-released consumer diabetes health app, BlueStar® C, with the recently launched Samsung Health, a mobile one-stop shop for health and fitness, and with Samsung Gear, including smart watches and fitness trackers.

BlueStar C is the consumer version of WellDoc’s suite of diabetes products. Its feedback and messaging is driven by the same patented decision support engine and high-quality analytics as the company’s clinically-proven original BlueStar platform and shares many of the same key features of the company’s therapeutic product offerings, but with a distinct lifestyle focus.

Specifically, BlueStar C offers:

• individualized, real-time support for users in their day-to-day diabetes self-care;
• easy tracking of blood glucose readings, food, medications, physical activity and sleep;
• videos and other resources to help improve daily lifestyle choices; and,
• a progress report that can be shared with family members or health care teams

Read More

Learn about the Diabetes Wellness Program

The American Association of Diabetes Educators (AADE), partnered to incorporate the “AADE Diabetes Education Curriculum: A Guide to Successful Self Management” in the BlueStar® digital therapeutic platform. The curriculum, built around the AADE7 Self-Care Behaviors™, focuses on the seven primary areas of self-management: Healthy Eating, Being Active, Monitoring, Taking Medication, Problem Solving, Reducing Risks and Healthy Coping.

This partnership marks the first time AADE, a professional membership organization comprised of healthcare professionals from multiple disciplines dedicated to improving diabetes care through innovative education, management and support, has partnered with an organization to provide its curriculum in a consumer-friendly digital format.

Read More

Human API, the fastest-growing health data platform, partnered to explore the unique integration of type 2 diabetes patient health data within the BlueStar digital therapeutic platform. Human API’s data platform will provide real-time access to comprehensive clinical patient data from its network of 15,000+ pharmacies, health systems and laboratories. The steady flow of data is shared within a highly secure environment that ensures protection of data and patient privacy.

This partnership allows the seamless integration of medication, medical history and laboratory data from multiple sources with a patient’s consent but without requiring direct patient input – further optimizing the user experience and helping patients and their physicians make informed.

Read More

Ontario Telemedicine Network (OTN), a world leader in telemedicine along with Samsung Electronics in Ontario, Canada and WellDoc have launched an innovative demonstration program with BlueStar®.  The goal of the program is to demonstrate the clinical and economic value of integrating a clinically proven self-management tool and lifestyle tracking into the type 2 diabetes treatment standard of care. The program includes a minimum of 300 people living with type 2 diabetes who will receive a prescription of BlueStar-S from their healthcare provider.

The combined offering, called BlueStar-S, will empower OTN participants to feel confident in their management of type 2 diabetes by also integrating personal fitness goals and health metric tracking with S Health®. The tool can be used to track eating, exercise, and sleep to help maintain a healthy lifestyle. Unlike other apps in the market, BlueStar® is unique in its ability to deliver a customized diabetes self-management program that is tailored to each patient based on his or her provider’s treatment plan.

Read More

Voluntis and WellDoc®, two of the industry’s leading digital therapeutics companies, announced a commercial agreement aimed at combining Voluntis’ insulin titration technology with WellDoc’s extensive digital coaching platform to create a holistic digital diabetes management solution for patients, providers, health systems and health plans. 

Voluntis developed Insulia®, an FDA-cleared, prescription-only digital companion for people and their care teams using basal insulin to treat type 2 diabetes. It provides automated basal insulin dose recommendations for people with type 2 diabetes while enabling the health care team to remotely monitor progress. 

The developer of BlueStar® – an FDA-cleared, digital therapeutic for individuals with type 2 diabetes – WellDoc is the first digital health company in the US to conduct randomized clinical trials that demonstrate significant clinical outcomes, as published in multiple peer-reviewed journals and presented at leading industry conferences. The clinical evidence shows a 1.7 to 2.0- point mean A1C reduction for individuals living with type 2 diabetes who used BlueStar. 1 BlueStar provides real-time and timely individualized coaching and support, as well as educational tools that are actionable and personal for individuals living with type 2 diabetes. 

The pioneering companies maintain a shared vision of how digital technologies can positively impact the health of patients. In order to realize this goal, Voluntis and WellDoc are committed to clinical validation of their solutions, rigorous adherence to regulatory requirements, working with stakeholders to drive utilization and reimbursement, and collaboration with industry partners that complement each company’s respective solutions.

Read More